Literature DB >> 19998030

MEPE's diverse effects on mineralization.

Adele L Boskey1, Phyllis Chiang, Alexis Fermanis, Jared Brown, Hayat Taleb, Valentin David, Peter S N Rowe.   

Abstract

Matrix extracellular phosphoglycoprotein (MEPE) is an inhibitor of mineralization in situ and in cell cultures where altered expression is associated with oncogenic osteomalacia and hypophosphatemic rickets. The purpose of this study was to determine whether the intact protein or the peptide(s) originating from this protein was responsible for the inhibition. The ability of the intact protein and the acidic, serine- and aspartate-rich MEPE-associated motif (ASARM) peptide to promote or inhibit de novo hydroxyapatite formation and growth of hydroxyapatite seed crystals, in both phosphorylated and dephosphorylated forms, was assessed at room temperature in a dynamic gel diffusion system at 3.5 and 5 days. The most effective nucleator concentration was also examined when associated with fibrillar type I collagen. The phosphorylated intact protein was an effective promoter of mineralization in the gelatin gel diffusion system, while the ASARM peptide was an effective inhibitor. When dephosphorylated both the intact protein and the ASARM peptide had no effect on mineralization. Associated with collagen fibrils, some of the effect of the intact protein was lost. This study demonstrates the importance of posttranslational modification for the site-specific activity of MEPE and its ASARM peptide.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19998030      PMCID: PMC2810528          DOI: 10.1007/s00223-009-9313-z

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  28 in total

1.  Dentin sialoprotein (DSP) has limited effects on in vitro apatite formation and growth.

Authors:  A Boskey; L Spevak; M Tan; S B Doty; W T Butler
Journal:  Calcif Tissue Int       Date:  2000-12       Impact factor: 4.333

2.  Mepe, the gene encoding a tumor-secreted protein in oncogenic hypophosphatemic osteomalacia, is expressed in bone.

Authors:  L Argiro; M Desbarats; F H Glorieux; B Ecarot
Journal:  Genomics       Date:  2001-06-15       Impact factor: 5.736

3.  Targeted disruption of the osteoblast/osteocyte factor 45 gene (OF45) results in increased bone formation and bone mass.

Authors:  Lori C Gowen; Donna N Petersen; Amy L Mansolf; Hong Qi; Jeffrey L Stock; George T Tkalcevic; Hollis A Simmons; David T Crawford; Kristen L Chidsey-Frink; Hua Zhu Ke; John D McNeish; Thomas A Brown
Journal:  J Biol Chem       Date:  2002-11-05       Impact factor: 5.157

4.  MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia.

Authors:  P S Rowe; P A de Zoysa; R Dong; H R Wang; K E White; M J Econs; C L Oudet
Journal:  Genomics       Date:  2000-07-01       Impact factor: 5.736

5.  ASARM-truncated MEPE and AC-100 enhance osteogenesis by promoting osteoprogenitor adhesion.

Authors:  Andrew P Sprowson; Andrew W McCaskie; Mark A Birch
Journal:  J Orthop Res       Date:  2008-09       Impact factor: 3.494

6.  Inhibition of MEPE cleavage by Phex.

Authors:  Rong Guo; Peter S N Rowe; Shiguang Liu; Leigh G Simpson; Zhou-Sheng Xiao; L Darryl Quarles
Journal:  Biochem Biophys Res Commun       Date:  2002-09-13       Impact factor: 3.575

7.  Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP.

Authors:  Aline Martin; Valentin David; Jennifer S Laurence; Patricia M Schwarz; Eileen M Lafer; Anne-Marie Hedge; Peter S N Rowe
Journal:  Endocrinology       Date:  2007-12-27       Impact factor: 4.736

8.  Bone sialoprotein-collagen interaction promotes hydroxyapatite nucleation.

Authors:  Gurpreet S Baht; Graeme K Hunter; Harvey A Goldberg
Journal:  Matrix Biol       Date:  2008-06-24       Impact factor: 11.583

9.  MEPE has the properties of an osteoblastic phosphatonin and minhibin.

Authors:  P S N Rowe; Y Kumagai; G Gutierrez; I R Garrett; R Blacher; D Rosen; J Cundy; S Navvab; D Chen; M K Drezner; L D Quarles; G R Mundy
Journal:  Bone       Date:  2004-02       Impact factor: 4.398

10.  Matrix extracellular phosphoglycoprotein (MEPE) is a new bone renal hormone and vascularization modulator.

Authors:  Valentin David; Aline Martin; Anne-Marie Hedge; Peter S N Rowe
Journal:  Endocrinology       Date:  2009-06-11       Impact factor: 4.736

View more
  24 in total

1.  Separation of newly formed bone from older compact bone reveals clear compositional differences in bone matrix.

Authors:  Ronald J Midura; Sharon B Midura; Xiaowei Su; Jeffrey P Gorski
Journal:  Bone       Date:  2011-09-18       Impact factor: 4.398

Review 2.  The rachitic tooth.

Authors:  Brian L Foster; Francisco H Nociti; Martha J Somerman
Journal:  Endocr Rev       Date:  2013-12-04       Impact factor: 19.871

3.  Matrix extracellular phosphoglycoprotein is expressed in causative tumors of oncogenic osteomalacia.

Authors:  Yasuo Imanishi; Jun Hashimoto; Wataru Ando; Keisuke Kobayashi; Takafumi Ueda; Yuki Nagata; Akimitsu Miyauchi; Hajime M Koyano; Hiroshi Kaji; Takatoshi Saito; Koichi Oba; Yasato Komatsu; Tomoaki Morioka; Katsuhito Mori; Takami Miki; Masaaki Inaba
Journal:  J Bone Miner Metab       Date:  2011-07-08       Impact factor: 2.626

Review 4.  The osteocyte: an endocrine cell ... and more.

Authors:  Sarah L Dallas; Matthew Prideaux; Lynda F Bonewald
Journal:  Endocr Rev       Date:  2013-04-23       Impact factor: 19.871

5.  MEPE Localization in the Craniofacial Complex and Function in Tooth Dentin Formation.

Authors:  Angela Gullard; Jelica Gluhak-Heinrich; Silvana Papagerakis; Philip Sohn; Aaron Unterbrink; Shuo Chen; Mary MacDougall
Journal:  J Histochem Cytochem       Date:  2016-02-29       Impact factor: 2.479

6.  Post-translational modification of osteopontin: effects on in vitro hydroxyapatite formation and growth.

Authors:  Adele L Boskey; Brian Christensen; Hayat Taleb; Esben S Sørensen
Journal:  Biochem Biophys Res Commun       Date:  2012-02-10       Impact factor: 3.575

7.  Elevated solute transport at sites of diffuse matrix damage in cortical bone: Implications on bone repair.

Authors:  Bin Wang; Xuanhao Sun; Ozan Akkus; Liyun Wang
Journal:  J Orthop Res       Date:  2017-11-16       Impact factor: 3.494

8.  ASARM peptides: PHEX-dependent and -independent regulation of serum phosphate.

Authors:  Valentin David; Aline Martin; Anne-Marie Hedge; Marc K Drezner; Peter S N Rowe
Journal:  Am J Physiol Renal Physiol       Date:  2010-12-22

Review 9.  Is interaction between age-dependent decline in mechanical stimulation and osteocyte-estrogen receptor levels the culprit for postmenopausal-impaired bone formation?

Authors:  R Sapir-Koren; G Livshits
Journal:  Osteoporos Int       Date:  2012-11-15       Impact factor: 4.507

10.  Age dependent regulation of bone-mass and renal function by the MEPE ASARM-motif.

Authors:  Lesya V Zelenchuk; Anne-Marie Hedge; Peter S N Rowe
Journal:  Bone       Date:  2015-06-04       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.